Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30146% above fair value
$3.44−0.06 (-1.71%)
Close on Nov 20, 2026Market cap $506.36MP/E –Yield –
Aclaris Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Aclaris Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$62.18M. For fiscal 2025 it was -$47.22M. The highest annual figure on record is -$8.05M in fiscal 2014.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$47.22M | – |
| FY2024 | Dec 31, 2024 | -$20.20M | – |
| FY2023 | Dec 31, 2023 | -$79.63M | – |
| FY2022 | Dec 31, 2022 | -$68.17M | – |
| FY2021 | Dec 31, 2021 | -$52.44M | – |
| FY2020 | Dec 31, 2020 | -$39.09M | – |
| FY2019 | Dec 31, 2019 | -$98.06M | – |
| FY2018 | Dec 31, 2018 | -$102.17M | – |
| FY2017 | Dec 31, 2017 | -$55.90M | – |
| FY2016 | Dec 31, 2016 | -$34.84M | – |
| FY2015 | Dec 31, 2015 | -$20.88M | – |
| FY2014 | Dec 31, 2014 | -$8.05M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.96M | -149.8% |
| Q2 FY2025 | Jun 30, 2025 | -$10.01M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.94M | – |
| Q3 FY2024 | Sep 30, 2024 | $22.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.66M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.93M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.18M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.62M | – |
| Q1 FY2019 | Mar 31, 2019 | -$31.60M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.39M | – |
| Q3 FY2018 | Sep 30, 2018 | -$30.42M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.19M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -$18.79M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.98M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.85M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.13M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.97M | – |
See a number that looks wrong?